Mercer Global Advisors’s Gain Therapeutics GANX Stock Holding History

Mercer Global Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3K	Buy	+10,000	New	+$18.4K	﹤0.01%	4814

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Mercer Global Advisors's GANX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Gain Therapeutics (GANX) in Q2 2026: 10,000 shares worth $20.3K. The stake represents ﹤0.01% of the portfolio and ranks #4814 among its holdings.

42 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Mercer Global Advisors held 10,000 shares of Gain Therapeutics worth $20.3K as of Q2 2026.
Gain Therapeutics was a new Mercer Global Advisors position in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4814 holding.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.